Febuxostat and Cardiovascular Events: A Systematic Review and Meta-Analysis

Table 2

Major adverse cardiac events.

Author	Drug	n	Angina pectoris	HF	Ischemic Coronary artery disorder	Non-fatal MI	CV death	MACE
Dalbeth [21]	FBX 40 mg	157	0	1	1	1	1	4
	Placebo	157	0	1	1	0	1	3
Gunawardhana [22]	FBX 80 mg	61	0	0	1	0	0	1
	Placebo	60	0	0	0	0	0	0
Huang [32]	FBX 40 mg	172	0	0	0	0	0	0
	FBX 80 mg	172	0	0	0	0	0	0
	Allopurinol	172	1	0	0	0	0	1
Becker [38]	FBX 40 mg	757	2	2	4	0	0	8
	FBX 80 mg	756	0	0	2	1	0	3
	Allopurinol	756	0	1	4	1	2	8
Becker [39]	FBX 80 mg	606	0	3	17	0	4	24
	FBX 120 mg	388	0	3	3	0	2	8
	Allopurinol	92	0	1	2	0	0	3
Schumacher [40]	FBX 80 mg	267	0	0	3	0	0	5
	FBX 120 mg	269	0	0	2	0	0	5
	FBX 240 mg	134	0	0	0	0	0	1
	Allopurinol	268	0	0	0	0	0	1
	Placebo	134	0	0	1	0	0	1
Becker [41]	FBX 80 mg	256	0	3	3	0	1	7
	FBX 120 mg	251	0	1	2	0	1	4
	Allopurinol	253	0	0	6	0	0	6
Nakagomi [43]	FBX 40	31	0	0	2	0	0	2
	Allopurinol	30	0	0	3	0	0	3
Saag [44]	FBX 30 mg BID	32	0	1	0	0	0	1
	FBX 48/80 mg QD	32	0	1	0	0	1	2
	Placebo	32	0	0	0	1	1	2
White [10]	FBX up to 80	3098	0	0	49	111	134	294
	Allopurinol	3092	0	0	56	118	100	274

FBX: febuxostat; HF: heart failure; MACE: major adverse cardiovascular events. Reported as cardiovascular events (chest pain, coronary artery disease, myocardial infarction, and atrial fibrillation), not specified how many of each.